Mabqi & Abzena – Your Integrated Antibody Discovery Through Development Solution

One of the most common inflection points where antibody programs lose momentum isn’t in the lab — it’s at the handoff.

When discovery and development are managed as separate activities, programs absorb delays, repeat characterization work, and carry manufacturability risks that could have been flagged months earlier.

That’s the problem our strategic partnership with Mabqi is built to solve.

Together, we offer an integrated pathway from antibody discovery through IND/CTA — where Abzena’s development and CMC expertise operates alongside Mabqi’s LiteMab© platform from the start, not after sequence selection.

In practice, that means:

• Developability and immunogenicity assessment informing lead selection — not following it
• Top sequences transitioning directly into cell line development and process development with shared documentation
• Conjugation strategy for ADC programs aligned before final construct decisions
• Unified scientific governance across discovery, development, and manufacturing
• For early-stage companies, this addresses three recurring risks: selecting a lead that won’t scale, discovering manufacturability issues too late, and losing time between vendors.

The result is a more predictable path to the clinic — with fewer technical surprises and a single continuous process rather than a series of discrete contracts.

Access our brochure to discover how we can seamlessly advance your program to IND and beyond.

Speak with Our Experts About Your Antibody Program Today!

About Mabqi

Mabqi is a biotechnology company focused on the discovery and development of fully human antibodies. Leveraging an innovative platform, we specialize in uncovering monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), pH-sensitive antibodies, and various other immunotherapy formats. Learn more at mabqi.com.

Partnership Announcement: Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development Solution
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced the formation of a strategic partnership. This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution. Access the full press announcement.